

SURAB study: comparing ABlation with active SURveillance, in the management of incidentally diagnosed small renal tumours: a feasibility study

Submission date 25/07/2014	Recruitment status No longer recruiting	☒ Prospectively registered ☐ Protocol
Registration date 25/07/2014	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 09/03/2020	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

<http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-treatments-for-small-kidney-cancers-surab>

Contact information

Type(s)

Scientific

Contact name

Miss Ann Marie Hynes

Contact details

Clinical Trials Unit
Faculty of Medical Sciences
Newcastle University
1 – 4 Claremont Terrace
Newcastle upon Tyne
United Kingdom
NE2 4AE
+44 (0)191 208 7647
Ann.hynes@newcastle.ac.uk

Additional identifiers

Protocol serial number

17090

Study information

Scientific Title

SURAB study: a randomised study comparing Ablation with active SURveillance, in the management of incidentally diagnosed small renal tumours: a feasibility study

Acronym

SURAB

Study objectives

The aim of this study is to establish whether a future definitive trial comparing active surveillance with ablative treatment for small kidney cancer is feasible. There is also a pre-pilot qualitative component to the study which will inform trial design.

More details can be found at <http://www.nets.nihr.ac.uk/projects/hta/1110701>

Protocol can be found at http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0018/115560/PRO-11-107-01.pdf

Ethics approval required

Old ethics approval format

Ethics approval(s)

14/NE/0155; First MREC approval date 26/07/2014

Primary study design

Interventional

Study design

Randomised; Interventional; Design type: Process of Care, Treatment

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Cancer; Subtopic: Renal Cancer; Disease: Kidney

Interventions

Ablation, Currently, centres have tended to develop expertise in either cryotherapy or radiofrequency ablation; centres will therefore offer only one form of ablation (the one in which they have expertise). There will also be an opportunity for departments which offer microwave ablation to participate in the trial.; Active Surveillance, Participants will be monitored for the duration of the trial; Follow Up Length: 6 month(s); Study Entry : Single Randomisation only

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

The aim is to establish whether a future definitive trial comparing active surveillance with ablative treatment for small kidney cancer is feasible. This will be assessed quantitatively in terms of recruitment and retention rates and qualitatively in terms of the patients' experiences and understanding of the randomisation process and treatment options. Partition of reasons for loss to follow up, together with clinical data, will allow us to project likely retention at 5 years.

Key secondary outcome(s)

All secondary outcomes will be rehearsed during the pilot trial with a view to refining the choice of outcomes for the main trial, based on data yield and quality.

Outcome data collection in the pilot feasibility trial will be timed to coincide with routine clinical assessments and will be collected from patients at 4, 7 months post randomisation (3, 6 months post treatment).

The following secondary outcome questionnaires will be completed at baseline (within 14 days before randomisation) and at 3 and 6 months post treatment:

1. A general health questionnaire (SF-36)
2. Cancer specific health status and quality of life (FACT-G)
3. Anxiety and depression (STAI)

We have also developed and plan to test health economics data collection tools in the form of a participant costs questionnaire (PCQ). The PCQ has two parts: Part A to be administered at 3 months and 6 months and Part B at 6 months only.

Completion date

31/10/2016

Eligibility

Key inclusion criteria

1. Adult diagnosed with renal cancer < 4 cm (confirmation by radiology* or by biopsy)
 2. ASA physical status classification system grade 1 or 2
 3. Age ≥ 18 years of age
 4. CT/MRI abdomen/chest with no evidence of metastases
 5. Patient has provided written informed consent prior to any study specific procedures
- *Radiological confirmation requires noting an enhancing renal mass of >20 Hounsfield units.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

Current exclusion criteria as of 09/03/2015:

Patients the clinician does not feel would be suitable for the trial (e.g., due to concomitant disease)

1. Multiple small renal cancers in one kidney
2. Coagulopathy that cannot be corrected
3. Previous participation in this study
4. Inability to give informed consent; carer/proxy consent will not be allowed in this study

Previous exclusion criteria:

Patients the clinician does not feel would be suitable for the trial (e.g., due to concomitant disease)

1. Fuhrman grade 3 / 4
2. Multiple small renal cancers in one kidney
3. Coagulopathy that cannot be corrected
4. Previous participation in this study
5. Inability to give informed consent; carer/proxy consent will not be allowed in this study

Date of first enrolment

01/04/2015

Date of final enrolment

29/02/2016

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

For full details on participating centres please contact:

Clinical Trials Unit

Faculty of Medical Sciences

Newcastle University

1 – 4 Claremont Terrace

Newcastle upon Tyne

United Kingdom

NE2 4AE

Sponsor information

Organisation

Newcastle upon Tyne Hospitals NHS Foundation (UK)

ROR

Funder(s)

Funder type

Government

Funder Name

Health Technology Assessment Programme

Alternative Name(s)

NIHR Health Technology Assessment Programme, Health Technology Assessment (HTA), HTA

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Other

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/12/2017		Yes	No
HRA research summary			28/06/2023	No	No
Plain English results			09/03/2020	No	Yes